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Abstract (150 - 250 words) [165] 
 
Skeletal muscle is an organ involved in whole body movement and energy metabolism with the ability 
to dynamically adapt to different states of (dis-)use. At a molecular level, the peroxisome proliferator-
activated receptor  coactivators 1 (PGC-1) are important mediators of oxidative metabolism in 
skeletal muscle and in other organs. Musculoskeletal disorders as well as obesity and its sequelae are 
associated with PGC-1 dysregulation in muscle with a concomitant local or systemic inflammatory 
reaction. In this review, we outline the function of PGC-1 coactivators in physiological and 
pathological conditions as well as the complex interplay of metabolic dysregulation and inflammation 
in obesity with special focus on skeletal muscle. We further put forward the hypothesis that in this 
tissue, oxidative metabolism and inflammatory processes mutually antagonize each other. The nuclear 
factor κB (NF-B) pathway thereby plays a key role in linking metabolic and inflammatory programs 
in muscle cells. We conclude this review with a perspective about the consequences of such a negative 
















 Obesity has become a global epidemic and a large number of deaths can be attributed to 
obesity-related disorders commonly known as the “metabolic syndrome”. Understanding the 
molecular mechanisms underlying this syndrome is crucial to be able to develop appropriate treatment 
strategies and improve quality of life of patients. Skeletal muscle is important in glucose homeostasis 
as a large part of blood glucose is taken up into this tissue, stored as glycogen or used as substrate. 
Skeletal muscle insulin resistance is thus detrimental as it disturbs whole body glucose metabolism. 
The development of insulin resistance is closely linked to inflammation, which has been studied 
extensively in white adipose tissue. Macrophages and other cells of the immune system interact with 
cells of the resident tissue to promote or restrain inflammatory reactions. This fosters or impedes the 
genesis of insulin resistance, respectively. In skeletal muscle, these processes and their 
interdependence have just started to be elucidated.  
 PGC-1 coactivators are transcriptional coregulators that facilitate expression of an oxidative 
metabolic program in energy-demanding organs including skeletal muscle, in particular in adaptation 
to endurance training. Many skeletal muscle pathologies, for example muscle wasting, are associated 
with PGC-1 repression and accompanied by inflammatory reactions in muscle tissue. PGC-1 
downregulation has also been observed in skeletal muscle of diabetic patients that display higher 
levels of pro-inflammatory cytokines both in muscle and blood, a situation that is recapitulated in mice 
that lack PGC-1. Inversely, exercise is known to promote anti-inflammatory effects and PGC-1 
coactivators recently have been shown to have anti-inflammatory properties in vitro. 
 In the current review, we therefore examine the influence of inflammation on PGC-1 
coactivators and vice versa focusing on skeletal muscle. We provide thorough background information 
on all the relevant areas including skeletal muscle physiology and pathology, PGC-1 coactivator 
regulation and function and the molecular basis of inflammatory reactions. We then explore how 
oxidative metabolism and inflammatory processes are linked providing evidence for a mutual, 
negative regulation. This antagonism has far reaching consequences both for muscle and immune 
cells, positioning skeletal muscle at the cross road of metabolic and inflammatory processes. 
 
 
1 Skeletal muscle 
 
1.1 Skeletal muscle structure and function 
 
 The human body contains different types of muscle, mainly skeletal muscle, cardiac muscle 
and smooth muscle that all have the ability to contract. While cardiac and smooth muscle contraction 
is involuntary, skeletal muscle contraction can be controlled deliberately as it contributes 
fundamentally to locomotion and posture. 
 To fulfill these purposes, skeletal muscle is attached to the bone by tendons, enveloped by a 
layer of connective tissue (the epimysium) and organized in several functional units. The largest unit is 
the muscle bundle. Each skeletal muscle comprises several bundles, so-called fasciculi, which are 
confined by the perimysium, another layer of connective tissue. The second functional unit is the 
myofiber, a postmitotic, syncytial muscle cell, itself lined by connective tissue (the endomysium). 
Multiple myofibers run in parallel to form a bundle. Each myofiber contains numerous myofibrils, the 
smallest functional unit of skeletal muscle. Myofibrils are linear sequences of sarcomers, which are the 
fundamental contractile element of muscle cells. Under the microscope, these sarcomere repeats 
appear as distinct bands giving skeletal muscle its unique, striated pattern. At a molecular level, 
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sarcomers are composed of the interdigitating myofilaments myosin and actin, which contract by 
sliding along each other and thereby shorten the muscle [1].  
 Skeletal muscles are innervated by motor neurons, which originate in the spinal cord. The 
synapse between motor neuron and muscle constitutes the neuromuscular junction. One motor neuron 
and all muscle fibers that are innervated by this neuron are called a motor unit. All fibers of a motor 
unit always contract in conjunction upon excitation of the innervating motor neuron. This excitation 
manifests in an action potential which leads to release of the neurotransmitter acetylcholine into the 
synaptic cleft at the neuromuscular junction. Postsynaptically, acetylcholine binds to its receptor, a 
ligand-gated ion-channel, and evokes an end plate potential by depolarization. This potential 
propagates along the fiber membrane (sarcolemma) which has deep invaginations (transverse tubules) 
harboring voltage-gated dihydropyridine receptors. These receptors in turn activate ryanodine 
receptors in the adjacent sarcoplasmic reticulum (SR) leading to a release of calcium from this 
compartment. Increased intracellular calcium concentrations finally initiate contraction. The close 
proximity of dihydropyridine receptors in the sarcolemma of transverse tubules and ryanodine 
receptors in the SR enables excitation-contraction coupling [1].  
 Contraction requires the binding of myosin to actin filaments. In the basal state, the binding 
sites (active sites) are however masked by the troponin-tropomyosin complex thus hindering 
interactions. Binding of calcium to troponin exposes the active sites and enables myosin heads to form 
cross bridges which subsequently move, hence sliding the myofilaments against one another. The 
cross bridges are released by binding of ATP allowing another cycle of contraction. Contraction ends 
when calcium is pumped back to the SR and no further actin-myosin interactions occur [1]. 
 
 
1.2 Metabolic characteristics of skeletal muscle  
 
 Myosin filaments in skeletal muscle contain six subunits, two heavy chains and four light 
chains, whereby different types of myosin heavy chains (MHC) can be distinguished. They vary in 
their contractile characteristics and are prototypical for different types of muscle fibers, which are 
adapted to different kinds of contraction. Type I or slow fibers that contain MHC I contract with low 
maximal force but are highly resistant to fatigue while type II or fast fibers that contain MHC II 
fatigue rapidly but are able to produce a high maximal force. Type I fibers appear red due to a high 
level of vascularization while type II fibers appear white. The latter can be further subdivided into type 
IIa (moderately fast), type IIx (intermediate) and type IIb (very fast) fibers. According to their 
contraction properties, the various fiber types primarily rely on different metabolic pathways as energy 
source: while type I and IIa fibers are oxidative, type IIx and IIb fibers are glycolytic [1]. 
 Glycolytic fibers mainly metabolize glucose, which is taken up into muscle cells by glucose 
transporters (GLUT), some of which translocate to the membrane upon higher energy demand. In the 
cytosol, glucose is then converted into pyruvate by glycolysis producing ATP via substrate-level 
phosphorylation. As glycolytic fibers contain few mitochondria, pyruvate is further transformed 
anaerobically into lactic acid recovering the pool of NAD+, an essential cofactor of glycolysis [2]. This 
process enables very fast supply of energy for intensive bursts of work, however only for limited 
periods of time. Type II muscle fibers are thus typical for strength athletes.  
 At the other end of the spectrum, oxidative fibers contain a high number of mitochondria, 
which are the main site of aerobic energy production. The mitochondrial matrix harbors enzymes of 
fatty acid  oxidation and the citric acid cycle while the mitochondrial inner membrane comprises the 
components of the electron transport chain. Fatty acids are the main energy substrate of oxidative 
fibers besides glucose. They are taken up into muscle cells by fatty acid translocase CD36, activated in 
the cytosol and shuttled into mitochondria as acylcarnitines. Fatty acid  oxidation then generates 
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acetyl-CoA that is fed into the citric acid cycle producing NADH, which serves as electron donor of 
the electron transport chain (complex I-IV) with oxygen being the final acceptor. The energy liberated 
during the electron passage is stored as an electrochemical proton gradient across the inner 
mitochondrial membrane and ultimately dissipated by the ATP synthase that drives aerobic ATP 
production [2]. 
 ATP fuels muscle contraction because it enables the release of myosin-actin interaction which 
is a prerequisite for the subsequent contraction cycle whereas ATP depletion results in muscle fatigue 
and the inability to sustain performance. In addition, ATP is required for various other processes that 
are important for muscle contraction, for example ATP-driven re-uptake of calcium into the SR. The 
availability and utilization of energy substrates is therefore vital for continuous contraction. As 
oxidative metabolism in type I muscle fibers is well-adapted to prolonged periods of intermediate 
workloads, these fibers are characteristic for endurance athletes.  
 
 
1.3 Obesity-related changes in skeletal muscle  
 
 Skeletal muscle is the main site of glucose disposal in the body and therefore contributes 
substantially to whole-body glucose homeostasis. In metabolic diseases, glucose homeostasis becomes 
dysregulated resulting in hyperglycemia due to elevated levels of hepatic gluconeogenesis and 
diminished levels of glucose uptake into target tissues like skeletal muscle and fat. The deficit in 
glucose uptake stems from progressive insulin resistance of target tissues that precedes the exhaustion 
of insulin-producing pancreatic  cells in type 2 diabetes [3].  
 Overnutrition raises free fatty acid levels in the circulation. Target cells including myocytes 
are unable to deal with the constant oversupply of lipids as it exceeds their capacities to oxidize fatty 
acids in mitochondria or store them as triglycerides. Therefore, lipid metabolites like diacylglycerol 
and ceramides accumulate within the cell. These lipids activate serine kinases, for example protein 
kinase C (PKC) that may phosphorylate insulin receptor substrate 1 (IRS1) at inhibitory serine 
residues [3]. In healthy muscle, IRS1 is phosphorylated at tyrosine residues upon insulin binding to its 
receptor. This in turn initiates phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) and subsequent 
protein kinase B (PKB)/Akt activation, which finally phosphorylates GLUT4 leading to membrane 
translocation and glucose uptake into the cell. Inhibitory IRS1 serine phosphorylation in obesity blunts 
this signaling cascade as it prevents the required tyrosine phosphorylation events and therefore causes 
insulin resistance [3]. Indeed, intramyocellular lipid levels strongly correlate with insulin resistance. In 
non-diabetic subjects, insulin resistance initially may be compensated for by hyperinsulinemia in order 
to preserve normal glucose tolerance. Aggravated insulin resistance and  cell dysfunction then mark 
the transition to overt type 2 diabetes where glucose tolerance is lost. 
 Mitochondria produce reactive oxygen species (ROS) as byproducts of cellular respiration 
when oxygen is reduced prematurely. The excess of fatty acids in skeletal muscle of obese patients and 
the associated overload of mitochondria leads to higher rates of ROS generation. Together with an 
insufficient ROS detoxification, this creates an environment of permanent oxidative stress [4]. Apart 
from the direct damage that ROS inflict upon macromolecules like DNA, proteins and lipids, oxidative 
stress also activates a number of cellular stress pathways including c-Jun N-terminal kinases (JNK) 
and p38/mitogen-activated protein kinases (MAPK) [4]. These serine kinases directly target IRS1 at 
inhibitory residues and thus bring about skeletal muscle insulin resistance. Furthermore, the nuclear 
factor B (NF-B) pathway is redox-sensitive. Activation of JNK, p38/MAPK and NF-B 
additionally induces transcription of inflammatory factors that substantially contribute to the 
development of insulin resistance. The exact role of inflammation in obesity and type 2 diabetes will 
be outlined below.  
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 The endoplasmic reticulum (ER) is responsible for synthesis, correct folding and secretion of 
proteins within the cell. It also plays an important role in calcium homeostasis, which is especially 
relevant in myocytes as calcium release from the SR initiates contraction. ER stress arises when this 
organelle is overburdened. Consequently, the unfolded protein response (UPR) acts as adaptive 
mechanism to resolve ER stress by reducing protein synthesis, increasing protein degradation and ER 
folding capacities through higher chaperone levels [5]. If chronically active, the UPR also induces NF-
B and JNK signaling, which both cause transcription of inflammatory factors and inhibitory IRS1 
phosphorylation events leading to insulin resistance. ER stress may also heighten ROS levels, which 
again has a negative influence on insulin sensitivity.  
 The accumulation of lipid derivatives in skeletal muscle of obese patients leads to 
considerable ER stress, which is also evident in vitro when treating muscle cells with palmitate [6, 7]. 
Tunicamycin-induced, profound ER stress dampens insulin action in myocyte cultures by evoking 
JNK and mammalian target of rapamycin (mTOR)/S6 kinase-1 (S6K1) signaling, which both target 
IRS1 serine residues [6]. Whether the same pathways are active in muscle cells treated with palmitate 
is less clear, however, and the contribution of ER stress to the development of insulin resistance under 




2 The PGC-1 family  
 
2.1 Molecular characteristics of PGC-1 coactivators  
 
 Transcription is a tightly regulated process that involves the binding of transcription factors to 
response elements in the promoter region of target genes. Those transcription factors subsequently 
attract chromatin remodeling enzymes and the RNA polymerase complex to the promoter in order to 
initiate transcription. Transcriptional activation is further fine-tuned by coregulators that either 
facilitate (coactivators) or hinder (corepressors) initiation.  
 The peroxisome proliferator-activated receptor (PPAR)  coactivator 1 (PGC-1) family 
comprises three members, PGC-1, PGC-1 and PGC-1-related coactivator (PRC) that all act as 
transcription coactivators. Their common structure features an N-terminal activation domain (AD), 
one or several LXXLL or LLXXL motifs (where L is leucine and X is any amino acid) that represent 
the interface for nuclear receptor (NR) binding, a serine-rich or arginine-/serine-rich domain, and a C-
terminal RNA recognition and splicing motif (Fig. 1). PGC-1 and PGC-1 also contain an inhibitory 
domain of about 200 amino acids adjacent to the AD. Two glutamine-rich domains are further 
characteristic for PGC-1, while PRC has a unique proline-rich domain (Fig. 1) 
 The PGC-1 coactivators do not harbor a DNA binding domain, but interact with specific 
transcription factors and NRs. PGC-1 was originally discovered as cofactor of PPAR and thyroid 
hormone receptor (TR) [8]. Subsequent studies identified most NRs as PGC-1 binding partners, 
including PPAR, PPAR/, liver X receptor (LXR), farnesoid X receptor (FXR), vitamin D receptor 
(VDR), constitutive androstane receptor (CAR), pregnane X receptor (PXR), estrogen receptor  
(ER), estrogen-related receptor  (ERR) and ERR, glucocorticoid receptor (GR), hepatic nuclear 
factor 4  (HNF4), and retinoid X receptor (RXR) [9-20]. This interaction can be either constitutive 
or ligand-dependent and indeed, human PGC-1 was identified in a screen for steroid-responsive 
genes [21]. PGC-1 is further able to coactivate a number of non-NR transcription factors like 
forkhead box protein O1 (Fox O1), FoxO3a, nuclear respiratory factor 1 (NRF1), myocyte-specific 
enhancer factor 2A (MEF2A), and MEF2C [22-26]. They bind PGC-1 via domains that are distinct 
from the LXXLL motifs.  
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 PGC-1 interacts with the NRs PPAR, ER, ERR and ERR, the transcription factors 
sterol regulatory element-binding protein 1a (SREBP1a) and SREBP1c, and FoxA2 [27-33]. Finally, 
PRC is able to potentiate ERR- and NRF1-dependent transcription [34, 35].  
 Mechanistically, after binding to NRs or transcription factors, the PGC-1 coactivators act as 
recruitment platform for protein complexes that further boost transcription. The details of this 
assembly have been explored meticulously for PGC-1: The AD interacts with the histone 
acetyltransferases (HATs) steroid receptor-1 (SRC-1) and cyclic AMP response element-binding 
protein (CREB) binding protein (CBP)/p300, which mediate decondensation of chromatin [36]. BRG-
1-associated factor 60a (BAF60a) tethers the chromatin remodeling switch/sucrose nonfermentable 
(SWI/SNF) complex to a central stretch within the PGC-1 protein, while the C-terminal region binds 
the TR-associated protein (TRAP)/vitamin D receptor-interacting protein (DRIP) or Mediator complex 
that directly associates with the basal transcription machinery and thus contributes to preinitiation 
complex formation [37, 38].  
 The positive effect of PGC-1 coactivators on transcription can be abrogated by nuclear 
corepressors that compete for binding sites on NRs and thus displace the coactivators. Examples 
include small heterodimer partner (SHP), SHP interacting leucine zipper protein (SMILE), and 
dosage-sensitive sex reversal adrenal hypoplasia congenital critical region on X chromosome, gene 1 
(DAX-1) [39-42]. Beyond the initiation of RNA polymerisation, PGC-1 is also implicated in RNA 
processing via the RNA recognition and splicing domain at the C-terminus [43]. 
 Several isoforms of PGC-1 coactivators are currently known (Fig. 1). Alternative splicing 
gives rise to NT-PGC-1 (amino acids 1-270), and to PGC-1-a and PGC-1-b (differing in exon 11) 
while alternative promoter usage generates PGC-1-1 (comprising exon 1a) and PGC-1-2 
(comprising exon 1a’ and exon 1b) [44, 45]. PGC-1 can also be transcribed from either the proximal 
or the alternative promoter (about 13kb upstream) resulting in expression of PGC-1-a/PGC-11 
(proximal promoter, exon 1), PGC-1-b/PGC-12 (exon 1b’’), PGC-1-c/PGC-13 (exon 1b’) and 
PGC-14 (exon 1b’’), the last three all originating at the alternative promoter [46-48] (Fig.1). In 
skeletal muscle, PGC-1-b/PGC-12 and PGC-1-c/PGC-13 are involved in adaptations to 




2.2 Regulation of PGC-1 activity  
 
 As PGC-1 coactivators are potent inducers of transcription, their activity and expression levels 
are tightly controlled within the cell. Post-translational modifications (PTMs) and intracellular 
signaling events are by far best-studied for PGC-1 and will be outlined in the following sections.  
 Different transcription factors control the synthesis of PGC-1 mRNA: CREB is a potent 
inducer of PGC-1 expression in different tissues and binds to cAMP response elements (CRE) in the 
promoter region of PGC-1 when phosphorylated by protein kinases [49]. In skeletal muscle, 
exercise-mediated calcium release activates calcium/calmodulin-dependent protein kinase type IV 
(CaMK IV), which targets CREB and thereby augments PGC-1 transcription [50]. 
 MEF2C and MEFD are able to bind to MEF2 sites in the PGC-1 promoter and elevate PGC-
1 expression. Free, cytosolic calcium not only activates CaMK IV in skeletal muscle but also the 
phosphatase calcineurin A (CnA), which boost the activities of MEF2C and MEF2D. These 
transcription factors are bound and coactivated by PGC-1 at its own promoter constituting a positive, 
autoregulatory feed-forward loop [50]. Exercise also activates p38/MAPK, which participates in PGC-
1 transcriptional regulation at two places: p38/MAPK phosphorylates both MEF2C/D and activating 
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transcription factor 2 (ATF2), thereby facilitating their binding to the PGC-1 promoter and further 
boosting transcription [51, 52]. Direct PGC-1 phosphorylation will be discussed below. 
 As a sensor of low energy levels in the cell, AMP-activated protein kinase (AMPK) is also 
activated upon muscle contraction and promotes PGC-1 expression [53]. Another autoregulatory 
loop has been described for PPAR/: PGC-1 heightens both PPAR/ and its own expression by 
coactivating this NR at the PGC-1 promoter [54]. PPAR and PPAR are part of similar 
autoregulatory mechanisms in other organs, which therefore appear to be a common strategy in the 
induction of PGC-1 expression [54, 55].  
 Reciprocally, transcription of the PGC-1 gene can be inhibited by several factors. In 
hepatocytes, insulin-stimulated Akt targets FoxO1, which as a result dissociates from the PGC-1 
promoter [56]. The recruitment of chromatin remodeling enzymes and transcription corepressors to the 
promoter also influences PGC-1 expression levels. Binding of histone deacetylases (HDACs) like 
HDAC5 to MEF2 compromises transcription as does the presence of SHP and nuclear corepressor 1 
(NcoR1) [57-59]. A more general mechanism of repression is hypermethylation of non-CpG 
nucleotides in the PGC-1 promoter, which is caused by DNA methyltransferase 3B (DNMT3B) [60]. 
 The second important aspect defining the transcriptional coactivator potential of PGC-1α is 
the modulation of PTMs that regulate protein stability and the binding affinity to transcription factors. 
A number of PTMs of PGC-1α have been reported, including phosphorylation, acetylation, 
methylation, GlcNAcylation, sumoylation and ubiquitination.  
 Kinases target several serine and threonine residues within the PGC-1 protein. AMPK- and 
p38/MAPK-dependent phosphorylation stabilizes PGC-1α and decreases the interaction with the 
repressor p160 myb binding protein (p160 mbp) [53, 61, 62]. As both kinases also affect PGC-1 
transcription, they have a dual effect involving an acute (phosphorylation) and a more sustained 
(expression) response. Similarly, PKA phosphorylates NT-PGC-1, a short transcript variant of PGC-
1α, and at the same time CREB, again constituting a dual, positive mode of action [63]. Akt and 
glycogen synthase kinase 3 (GSK3) both mediate inhibitory PGC-1 phosphorylation events [64, 
65]. Prior negative phosphorylation is also required for polyubiquitination of PGC-1 which targets 
the protein for proteasomal degradation [66]. 
 The acetylation status of PGC-1 further affects its activity. Acetyltransferase general control 
of amino acid synthesis 5 (GCN5) acetylates PGC-1 at multiple lysine residues thus rendering it 
inactive due to relocalisation to nuclear foci, while NAD+-dependent protein deacetylase sirtuin 1 
(Sirt1) removes these inhibitory acetyl residues [67-69]. As Sirt1 and AMPK are both sensors of 
cellular energy status, they act in concert to coordinately activate PGC-1 [70].  
 SUMOylation of PGC-1 does not change its subcellular localization or stability, but 
presumably facilitates interaction with receptor-interacting protein 140 (RIP140), a known repressor of 
PGC-1 [71, 72]. Finally, O-linked -N-acetylglucosylation and arginine methylation of PGC-1 
contribute to sustained transcription activity of this coactivator [73, 74]. 
 The multitude of PTMs is a result of the complex signaling network that converges on PGC-
1. Uncovering mutual influences and resolving the chronology of events in different organs in 
greater detail remains to be done.  
 
 
2.3 Role of PGC-1 coactivators in oxidative metabolism and skeletal muscle function 
 
 PGC-1 orthologs are present in all vertebrates species, with 95% sequence homology 
between mouse and human, and a high degree of conservation in the AD and NR interaction domain 
[21, 75]. In Drosophila, the PGC-1 homologue spargel is essential for mitochondrial gene expression 
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and spargel mutants display respiration defects [76]. This fundamental role of PGC-1 coactivators in 
cellular respiration is conserved across species, redundant between all 3 family members and 
important in all tissues that express PGC-1 coactivators. PGC-1 and PGC-1 are primarily enriched 
in organs with high oxidative capacity like skeletal muscle, heart, brown adipose tissue (BAT), kidney, 
and brain whereas PRC is found ubiquitously [8, 27, 35]. Hence, it appears that the coordination of 
oxidative metabolism is the central property of the PGC-1 family.  
 Mitochondrial biogenesis is necessary to meet higher energy demands in a cell. This complex 
process requires transcription of nuclear genes, import of the resulting proteins into mitochondria, 
transcription of mitochondrial DNA and its replication. PGC-1 coactivators integrate these events in 
cooperation with nuclear transcription factors 1 (NRF-1), NRF-2 (also called GA-binding protein or 
GABP) and ERR that induce nuclear-encoded mitochondrial genes like cytochrome c oxidase 
subunit 4 (COX IV), -ATP synthase, and mitochondrial transcription factor A (Tfam) [24, 29, 34, 35, 
77]. In turn, Tfam governs transcription and replication of mitochondrial DNA. 
 PGC-1 also induces NRF-1, NRF-2 and ERR at the expression level [25, 78]. Further 
signal amplification occurs through NRF-2 and ERR which boost their own and each others’ 
transcription respectively, to promote mitochondrial biogenesis in biological switches [79].  
 Surprisingly however, mice with a global deletion of either PGC-1 or PGC-1 are viable, 
fertile and do not show overtly deranged mitochondria [80-83]. Their ability to cope with different 
stress conditions (for example exposure to cold) is however grossly compromised. This indicates that 
PGC-1 coactivators are less required for basal mitochondrial function but are instrumental in 
orchestrating adaptations to environmental challenges. 
 Interestingly, the PGC-1 coactivators affect mitochondrial function in a specific manner. 
During electron transport, protons may leak over the inner mitochondrial membrane. Ectopic 
expression of PGC-1 in muscle cells promotes this leakage to a larger extend than PGC-1 although 
their effect on respiration is comparable [84]. 
 Mitochondrial biogenesis is accompanied by an increase in ROS production. To alleviate the 
resulting oxidative stress, PGC-1 and PGC-1 enhance the expression of ROS detoxifying enzymes 
like glutathione peroxidise 1 (GPx-1) and mitochondrial superoxide dismutase [Mn], (Sod2). 
Accordingly, PGC-1 acts neuroprotectively under oxidative stress conditions [85].  
 Higher rates of oxidative phosphorylation require elevated substrate supply. PGC-1 and 
PGC-1 augment fatty acid oxidation by coactivating ERR and PPAR in a constitutive and a 
ligand-dependent manner, respectively, which propagates the expression of key enzymes of this 
process such as medium-chain specific acyl-CoA dehydrogenase (MCAD) [9, 17, 86]. In addition, 
PGC-1 fosters peroxisome biogenesis, an organelle that catabolizes very long and branched chain 
fatty acids [87]. In summary, PGC-1 coactivators drive a whole program of oxidative metabolism to 
provide sufficient amounts of energy to the cell. 
 In skeletal muscle, PGC-1 is abundant and particularly enriched in slow twitch, oxidative 
muscle fibers that contain a large number of mitochondria. Forced expression of PGC-1 converts 
white muscles with mainly fast fibers into red muscles with properties of slow-twitch type I and IIa 
fibers while PGC-1 provokes a fiber type switch to type IIx fibers [88, 89]. In agreement with its role 
in oxidative myofiber determination, PGC-1 is transiently induced in skeletal muscle after a single 
bout of endurance exercise and chronically elevated in endurance trained muscle both in rodents and 
humans [90-92].  
 Many, if not all major adaptations of skeletal muscle in response to endurance training are 
mediated by PGC-1 which therefore represents an important point of convergence in the exercise-
triggered signaling network. The formation of a larger proportion of oxidative fibers requires 
mitochondrial biogenesis, fatty acid uptake (e.g. by CD36) and oxidation (e.g. by MCAD) in the 
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myocyte to ensure adequate substrate supply. All of these processes are coordinately regulated by 
PGC-1α [93, 94]. PGC-1 also augments GLUT4 expression in vitro and in vivo yielding higher 
glucose uptake into muscle cells [26, 94]. Pyruvate dehydrogenase kinase 4 (PDK4) is induced 
concomitantly to promote fatty acid oxidation at the expense of glucose metabolism [95]. Excess 
glucose that cannot be diverted into glycolysis is consequently stored in the form of glycogen and 
funneled into the pentose phosphate pathway [94, 96, 97]. The resulting elevation of NADPH and the 
PGC-1α-mediated activation of fatty acid synthase boost de novo lipogenesis and thus increased 
storage of intramyocellular lipids that serve as energy substrate. Thereby PGC-1α coordinates anabolic 
and catabolic metabolic pathways in skeletal muscle [98]. 
 Elevated ROS are a byproduct of higher mitochondrial activity in contracting skeletal muscle. 
As ROS reinforce PGC-1 expression, which contributes to ROS detoxification by raising enzymes 
like Sod2 (see above), this negative feed-back loop protects myocytes effectively from oxidative stress 
[99, 100].  
 Apart from metabolic fluxes within the cell, PGC-1 also tightly links muscle and nerve by 
regulating neuromuscular junction genes and promoting acetylcholine receptors clustering at the motor 
end plate [101]. In addition, PGC-1α tiggers a remodeling of calcium handling in muscle cells towards 
a slow fiber-type phenotype [102]. Finally, PGC-1 further affects angiogenesis by potently inducing 
vascular endothelial growth factor (VEGF) expression to maintain nutrient and oxygen supply to 
muscles during sustained contractions [103, 104]. 
 In combination, all of these PGC-1-mediated changes functionally translate into a higher 
endurance capacity as observed in PGC-1 skeletal muscle-transgenic mice whereas skeletal muscle-
specific deletion of PGC-1 decreases performance [96, 105]. 
 The regulation and function of PGC-1β is much less clear. For example, PGC- is not 
uniformly influenced by exercise. Nevertheless, when overexpressed in skeletal muscle, genes 
involved in oxidative phosphorylation and fatty acid oxidation are also upregulated by PGC-1β 
resulting structurally in a higher mitochondrial density and functionally in a better endurance 
performance [89]. Inversely, skeletal muscle-specific PGC-1 deletion causes lower endurance 
capacity [106]. A combined deficiency of PGC-1 and PGC-1 in a global PGC-1α and a muscle-
specific PGC-1β knockout background aggravates this phenotype displaying a very severe exercise 
deficit, strongly reduced oxidative capacity and mitochondrial structure and function derangements. 
However, fiber type determination is only slightly changed in these mice [106]. Similar to PGC-1, 
PGC-1 was also shown to enhance angiogenesis [107]. It therefore appears that PGC-1 and PGC-1 
share some properties in skeletal muscle and can potentially compensate for one another in some 
cases. The role as “exercise factor” is however unique to PGC-1 and such a clear physiological 
function has not been assigned to PGC-1 so far. 
 Aside from the regulation of endurance adaptations, PGC-1 is a target of the myogenic 
regulatory factor MyoD in terminal muscle differentiation and plays a role in regulating circadian 
clocks in muscle [108, 109]. Interestingly, MyoD itself is under the control of circadian transcription 
activators and their disruption perturbs muscle function as well as PGC-1 and PGC-1 expression 
[110]. Further studies are needed to investigate the mutual dependencies of PGC-1 coactivators, MyoD 
and clock genes to define their contribution to skeletal muscle physiology. 
 
 
2.4 Other organ-specific functions of PGC-1 coactivators 
 
 In addition to the regulation of oxidative metabolism, PGC-1 coactivators also execute an 
array of tissue-specific functions. In the liver, PGC-1 is markedly upregulated in response to fasting 
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and controls several important starvation pathways including gluconeogenesis and ketogenesis, [18, 
22, 49]. PGC-1 further governs hepatic heme, bile acid, selenoprotein P, and homocystein 
biosynthesis [111-114]. PGC-1 by contrast is central to lipid metabolism in the liver by inducing 
lipogenesis and the secretion of triglycerides/VLDL into plasma [31, 33].  
 Cardiac PGC-1 is augmented both in development when perinatally, fatty acids replace 
glucose as main source of energy, and in adult animals upon fasting. Lack of either PGC-1 or PGC-
1 promotes heart failure under stress conditions while a PGC-1β cardiac deficiency combined with a 
global PGC-1α gene ablation is lethal shortly after birth as those hearts are unable to mature [115-
118]. Inversely, cardiac PGC-1 overexpression causes disturbances in the sarcomere structure 
leading to dilated cardiomyopathy [119]. PGC-1 coactivator levels are thus only protective within a 
certain window of expression.  
 PGC-1 was originally discovered as thermogenic regulator in BAT induced by cold exposure 
[8]. BAT produces heat by uncoupled respiration whereas white adipose tissue (WAT) mainly stores 
energy in form of lipid droplets. Both PGC-1 and PGC-1 are critical for adequate BAT function and 
participate in brown fat lineage determination [118, 120, 121]. Induction of PGC-1 in WAT thus 
results in “browning” while PGC-1 suppression favors a white adipocyte phenotype [122-125]. 
Accordingly, mice with an adipose tissue-specific deletion of PGC-1 on high fat diet develop insulin 
resistance as the excess energy cannot be sufficiently dissipated [126]. 
 In pancreas, both PGC-1 and PGC-1 are involved in glucose-stimulated insulin secretion 
from  cells; their contribution is however controversial as suppression and induction of insulin 
release have been reported [32, 127, 128].  
 Both coactivators control mitochondrial density in nerve cells [129]. Neuroprotection through 
PGC-1 was shown in the contexts of oxidative stress and amyotrophic lateral sclerosis whereas 
neurodegeneration is associated with a loss of PGC-1 in various disorders including Huntington´s 
and Alzheimer´s disease [85, 130-132]. Consistently, global and brain-specific deletion models of 
PGC-1 exhibit striatal degenerative lesions and increased susceptibility for other neurodegenerative 
events [80, 133]. 
 PGC-1 also plays a role in light damage-induced retinal regeneration and function and in 
chondrogenesis [134, 135]. PGC-1 is further implicated in osteoclast activation and PRC has a non-
redundant function in proliferative growth [136, 137]. 
 
2.5 PGC-1 coactivators in skeletal muscle pathology 
 
 Skeletal muscle exhibits considerable plasticity and adapts to different training regiments as 
well as disuse. While endurance exercise induces PGC-1 as described above different experimental 
or pathological muscle wasting conditions like denervation-induced atrophy, statin treatment, diabetes, 
uremia, and cancer cachexia, reduce PGC-1 and/or PGC-1 levels [138-141]. Accordingly, ectopic 
expression of PGC-1 or PGC-1 counteracts the atrophic state by suppressing atrogenes in vitro and 
in vivo [140-142]. PGC-1 coactivators are thus able to preserve muscle structure and function under 
unfavorable circumstances. This observation extends to sarcopenia (progressive muscle loss with age) 
as old mice with transgenic PGC-1 expression in skeletal muscle show a higher degree of muscle 
integrity, improved mitochondrial function and better exercise performance than age-matched wild-
type animals [100].  
 Several inherited disorders affect skeletal muscle function. Duchenne muscular dystrophy 
(DMD) is caused by a mutation in dystrophin. Mutated dystrophin fails to link the cytoskeleton to the 
extracellular matrix leading to muscle degeneration and premature death. Mitochondrial myopathies 
stem from mutations in mitochondrial DNA. Skeletal muscle-specific overexpression of PGC-1 is 
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able to antagonize symptoms of both disorders in respective mouse models [101, 143]. PGC-1 
therefore dampens fiber damage and preserves muscle function in those contexts. A non-genetic 
approach deploying endurance training also raised PGC-1 levels and protected mice with 
mitochondrial myopathy [144].  
 The etiology of Huntington´s disease (HD) involves loss of muscle mass which coincides with 
a reduction of PGC-1 expression in rodents and humans. This wasting phenotype could be improved 
by artificially increasing PGC-1 levels in skeletal muscle [145].  
 Genetic and acquired obesity are strongly correlated with the development of insulin 
resistance and diminish both PGC-1 and PGC-1 levels in rodent skeletal muscle [146]. In human 
diabetic patients, a coordinate suppression of genes involved in oxidative phosphorylation has been 
observed concomitant with a reduction of PGC-1 and PGC-1 in some, but not all studies [147-149]. 
This suggests that dysregulated PGC-1 coactivator levels may account for disturbed energy 
metabolism in skeletal muscle contributing to the development of insulin resistance. Inversely, a 
moderate PGC-1 increase in skeletal muscle improves insulin sensitivity through the selective 
elevation of fatty acid oxidation in subsarcolemmal, but not intermyofibrillar mitochondria [150]. 
 The relationship between PGC-1 coactivators and insulin resistance is however more complex 
as two independent mouse strains lacking PGC-1 are less susceptible to diet-induced obesity possibly 
owing to hyperactivity, which is likely a consequence of striatal brain lesions [80, 81]. Skeletal 
muscle-specific deletion models still display higher peripheral insulin sensitivity, however, they do 
become glucose intolerant on a high fat diet. This puzzling phenotype is the result of muscle-islet 
crosstalk whereby muscle-derived IL-6 and possibly other factors might impair insulin secretion from 
pancreas leading to a deficit in glucose clearance from blood but at the same time to high insulin 
sensitivity in the periphery [151].  
 Surprisingly, muscle-specific PGC-1 overexpressing animals develop insulin resistance at an 
accelerated pace on high fat diet compared to wild-type mice presumably due to excess lipid storage 
within muscle cells [152]. Interestingly, the same model is however protected from sarcopenia and 
preserves insulin signaling and sensitivity until old age [100]. In a twin study, PGC-1 and PGC-1 
emerged as factors declining with age which might contribute to an increased risk of diabetes in this 
phase of life [153]. Dropping PGC-1 levels are associated with the common Gly482Ser variant but 
an unequivocal mechanistic link of this polymorphism to diabetes could not be established as the 
serine containing variant seems fully functional [154-156]. A polymorphism within the PGC-1 
promoter however clearly contributes to diabetes in Koreans and Austrians [157, 158]. 
 PGC-1 protects mice from genetic and acquired obesity, but without effect on whole-body 
glucose metabolism or skeletal muscle insulin sensitivity [29, 82, 159]. Loss of function however 
promotes hepatic insulin resistance because of lipid accumulation in the liver [82, 159]. Yet, genetic 
linkage studies failed to prove a clear association of the Ala203Pro variant with obesity or diabetes 
[160, 161]. 
 A PGC-1/PGC-1 double deficient model based on global PGC-1α and muscle-specific 
PGC-1β gene ablation surprisingly is unaffected in terms of glucose or insulin tolerance on different 
diets. Importantly however, the global PGC-1 deletion background confounds interpretation of these 
findings due to its complex brain phenotype [106]. 
 Pharmacological treatment of mice with resveratrol protects them from diet-induced obesity 
and insulin resistance as Sirt1-dependent PGC-1 activation stimulates oxidative metabolism in 
skeletal muscle [162, 163]. Furthermore, the insulin-sensitizing properties of thiazolidinediones are at 
least partially ascribed to an induction of PGC-1 and the concomitant restoration of mitochondrial 
bioenergetics in muscle e.g. in db/db mice [164]  
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 Targeting PGC-1 coactivators in skeletal muscle to fight musculoskeletal and metabolic 
diseases and especially increase insulin sensitivity is therefore a worthwhile venture. There is however 
a therapeutic window for these beneficial effects as excessive PGC-1 coactivator levels may act 
counterproductive [165]. Dysregulation of these coactivators in other organs further complicate 
treatment as for example in liver and pancreas of diabetic patients PGC-1 levels are increased which 
contributes to pathology in these tissues [165]. Finding potent and specific PGC-1 and PGC-1 





3.1 Major molecular pathways in inflammation 
 
 Inflammation is the protective response of the body to harmful insults like pathogens and 
wounding aiming at defense and repair to secure the organism’s integrity. The immune system has 
evolved to govern these inflammatory reactions and comprises two branches, innate and adaptive 
immunity, respectively. The innate immune system is able to react rapidly and initiate an 
inflammatory reaction within minutes. The adaptive immune system operates secondarily and thus 
delayed, but is highly specific. Immune cells communicate with injured or infected cells and other 
immune cells via small, soluble peptides, so-called cytokines, that may elicit, potentiate or dampen 
inflammation and thus fundamentally influence its progression. Potent pro-inflammatory cytokines 
include the tumor necrosis factor  (TNF), interleukin 1 (IL-1), IL-6, and macrophage 
inflammatory protein 1 (MIP-1) while IL-4, IL-10, IL-13 and IL-1 receptor antagonist (IL-1Ra) act 
primarily anti-inflammatory [166]. 
 To transmit their signals, cytokines bind to cytokine receptors. These are grouped into 
different families according to their structure. Type I and type II cytokine receptors are multimeric 
transmembrane receptors that signal via the janus kinase (JAK) - signal transducers and activators of 
transcription (STAT) pathway while chemokine receptors are G protein-coupled receptors (GPCRs) 
with seven transmembrane domains that signal through G proteins. Members of the TNF receptor 
(TNFR) family oligomerize upon ligand binding. They are associated with adaptor proteins that may 
activate inflammatory or apoptotic pathways via TNFR associated factors (TRAFs) and the caspase 
cascade, respectively. The transforming growth factor  (TGF) receptor family has three members 
that connect to SMAD proteins. Finally, some cytokine receptors belong to the immunoglobulin (Ig) 
superfamily.  
 Pathogens contain conserved structures, so-called pathogen-associated molecular patterns 
(PAMPs) that can be recognized by the host’s immune system to initiate inflammation. PAMPs bind 
to toll-like receptors (TLRs), which are expressed on the surface of immune and most other cells. So 
far, 12 mammalian TLRs with different binding specificities have been identified, e.g. TLR4 detecting 
lipopolysaccharide (LPS). TLRs signal through adaptor proteins like myeloid differentiation primary 
response gene 88 (Myd88) that further activate IL-1R-asscoiated kinases (IRAKs) and TRAFs finally 
leading to inflammation [167]. 
 While STATs and SMAD proteins are able to translocate to the nucleus and modulate 
transcription of inflammatory genes directly, GPCR signaling typically leads to the production of 
second messengers. TRAF activation downstream of TNFRs and TLRs causes activation of the NF-B 
pathway [167]. This pathway is central to inflammatory reactions and has been shown to be involved 
in a large number of diseases. NF-B activating signals converge at the inhibitor of B (IB) kinase 
(IKK) complex which comprises three subunits, IKK, IKK (both catalytic) and IKK/NF-B 
essential modulator (NEMO, regulatory). Canonical NF-B signaling involves activation of IKK, 
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which subsequently phosphorylates IB preexisting in a cytosolic complex with NF-B. 
Phosphorylation-induced polyubiquitination targets IB for proteasomal degradation consequently 
releasing NF-B that then translocates to the nucleus where it binds to B sites and thus promotes 
transcription of inflammatory genes [168].  
 NF-B binds DNA as homo- or heterodimer and five different NF-B family members are 
known: RelA/p65, RelB, c-Rel, p100/p52 and p105/p50 that all share an N-terminal Rel homology 
domain (RHD). P65, RelB and c-Rel additionally contain a transactivation domain (TAD) which 
facilitates transcription whereas p50 and p52 homodimers act repressive as they lack this domain. The 
most common and best studied NF-B dimer is p65/p50 [168].  
 Several ankyrin repeat domains are characteristic for the IB family. The typical members 
IB, IB and IB sequester NF-B dimers in the cytosol. They are degraded at different rates 
upon stimulation and also possess specific re-synthesis kinetics [169]. As NF-B target genes, the 
IκBs initiate a negative feedback loop to terminate NF-κB signaling [170]. The atypical IB family 
members IB, B-cell lymphoma 3 (Bcl3), and IB bind to NF-B dimers in the nucleus and 
modulate their transcription activation potential at this level [168]. The precursor proteins p100 and 
p105 can also be classified as IBs with ankyrin repeat domains despite constitutive processing to p52 
and p50 even in the basal state. P100 and p105 may also dimerize with other NF-B subunits e.g. 
RelB and c-Rel, respectively, retaining this complex in the cytosol in unstimulated cells. Stimulus-
dependent processing of p100 and p105 to p52 and p50 then yields active NF-B dimers [168]. 
 The canonical pathway described above involves the heterotrimeric IKK complex, IKK-
dependent phosphorylation of IB and subsequent release of p65/p50 [168, 171]. While IKK is 
dispensable for canonical signaling, it is required for noncanonical NF-B activation [172]. The 
noncanonical pathway is initiated by IKK dimers that phosphorylate p100 upon stimulation. As p100 
preexists in a complex with RelB, processing to p52 generates the RelB/p52 dimer, which is able to 
induce a subset of NF-B target genes [173]. Noncanonical NF-B activation has been described for 
example downstream of CD40, lymphotoxin  receptor (LTR), and B-cell activating factor receptor 
(BAFFR) [174-176].  
 PTMs of NF-B subunits also influence inflammatory signals and p65 has been studied 
extensively in this regard. Inducible phosphorylation, acetylation, ubiquitylation, prolyl isomerisation, 
poly(ADP-ribosyl)ation, monomethylation, and S-nitrosylation have been reported so far. Their 
presence affects the subcellular localization, the stability of DNA binding and the affinity to 
coactivator and corepressor complexes which determine the NF-B transcription activation potential 
[168].  
 Besides the NF-B pathway, activator protein 1 (AP-1) signaling plays an important role in 
inflammatory reactions. The induction of MAPK cascades e.g. downstream of TNFR and TLRs leads 
to activation of AP-1, which similar to NF-B is a homo- or heterodimeric transcription factor. The 
subunits belong to the Jun, Fos or activating transcription factor (ATF) families of basic-region 
leucine-zipper (B-ZIP) proteins that bind DNA at specific sequences and thus induce transcription of 
inflammatory target genes. A well-studied example is the activation of JNK, which in turn translocates 
to the nucleus where it phosphorylates c-jun thereby promoting AP-1’s transcription activation 
potential [177, 178]. 
 Finally, interferon regulatory factors (IRFs) mediate the induction of interferons and are as 
such critical in the response to viral infections [179].  
 The many players within the NF-B and AP-1 pathway illustrate the complexity and 
redundancy of inflammatory signaling. This complexity is necessary to allow the body to mount a 
highly specific immune response to different kinds of injury and infection in order to protect the body 
at all times. The nature of inflammation is transient and therefore termination of immune responses is 
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as important as initiation. If inflammatory reactions do not resolve and become chronic, they in fact 
turn detrimental and harmful to the body. Chronic inflammation also accompanies many pathologies 
including type 2 diabetes and cardiovascular diseases.  
 Inhibition of inflammation may occur at several levels. Changes in gene expression of the pro-
inflammatory transcription factors themselves and/or their upstream regulators affect inflammatory 
promoters. Examples are the resynthesis of IB proteins that retain NF-B in the cytosol and thus 
block transcription and the induction of repressive p50 or p52 homodimers that compete for B sites 
in the nucleus [168].  
 PTMs also interfere with inflammatory signaling. Suppressor of cytokine signaling 1 (SOCS1) 
for example is able to ubiquitinate p65 and its overexpression inhibits IL-1-dependent NF-B 
activation [180]. Then, A20-deficient mice develop severe inflammation because the dual ubiquitin 
editing enzyme A20 targets important signaling molecules like RIP1 and TRAF6 for degradation, 
thereby confining inflammatory processes [181, 182]. As phosphorylation events are important during 
the activation of most inflammatory pathways, changes in kinase and phosphatase activity influence 
pro-inflammatory gene expression. Again, the NF-B pathway provides excellent examples: IKK-
deficient MEFs can neither phosphorylate IB nor p65 while IKK-deficient MEFs normally 
degrade IB but are still unable to phosphorylate p65, which blunts transcription from NF-B-
inducible promoters [183]. Inversely, mice lacking Wip1, the only known p65-specific serine 
phosphatase, display increased NF-B target gene expression alongside higher p65 phosphorylation 
levels [184].  
 Transrepression by NRs has emerged as a potent mechanism to confine inflammation. 
Accordingly, PPAR activation reduces expression of IL-6, cyclooxygenase 2 (COX2), vascular cell 
adhesion molecule 1(VCAM1) and other inflammatory factors in different cell types whereas PPAR 
deletion renders mice hypersensitive to LPS [185-187]. PPAR ligands and glucocorticoids, activators 
of the GR, likewise exhibit strong anti-inflammatory effects [188-191]. In contrast to transactivation 
that requires direct NR-DNA binding, transrepression may occur indirectly without direct contact to 
DNA.  
 Several molecular mechanisms of transrepression were established so far. DNA-binding 
dependent or –independent induction of IB as shown for PPAR terminates NF-B target gene 
expression [192-194]. Moreover, competition for a limiting pool of coactivators like CBP results in 
mutual antagonism between inflammatory and NR pathways [195, 196]. NRs may also disrupt the 
coactivator complex at inflammatory transcription factors by binding either to the transcription factor 
thus preventing coactivator binding (e.g. GR on p65) or to the coactivator thus hindering its 
recruitment [197]. Additional cofactors like nuclear TR-interacting protein 6 may favor GR binding, 
which in turn promotes transrepression, while secondary recruitment of corepressors like glutamate 
receptor-interacting protein or CoREST propagate this state [198-200]. PPAR and LXR can further 
inhibit corepressor clearance from NF-B by preventing proteasomal degradation of NcoR1 in a 
ligand- and SUMOylation dependent manner [201, 202]. SUMOylation is also implicated in LXR-
mediated transrepression of STAT1 downstream of interferon signaling [203]. Furthermore, PPAR 
interacts with both c-jun and p65 to repress AP-1- and NF-B-driven gene expression, respectively 
[204]. As a consequence of this direct interaction, NR and inflammatory signaling pathways 
reciprocally interfere with each other constituting a negative cross-talk. Finally, GR may also constrain 
both transcription initiation and elongation by blocking RNA polymerase II hyperphosphorylation and 
chromatin remodeling by tethering HDACs to promoters of inflammatory genes [205-208].  
 
 
3.2 Obesity and inflammation  
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 Overweight and obesity do not only increase the risk for metabolic complications like insulin 
resistance but also foster a sterile, low-grade inflammation. This is evidenced by high plasma levels of 
circulating pro-inflammatory cytokines (IL-1, IL-6, IL-8, IL-12, and TNF), chemokines (monocyte 
chemoattractant protein (MCP) 1/CCL2, RANTES/CCL5, MIP-1), acute phase proteins (C-reactive 
protein, serum amyloid A, ferritin), adipokines associated with insulin resistance (retinol binding 
protein 4 and resistin), and procoagulative and hypertensive factors (plasminogen activator inhibitor 1 
and angiotensinogen) in obese patients [209]. Inversely, negative acute phase proteins (transcortin and 
transferrin) and adipokines associated with insulin sensitivity (adiponectin, visfatin, omentin, and 
vaspin) are lowered in plasma of those subjects [209]. 
 As expansion of adipose depots is the prime effect of obesity, an inflammatory reaction in 
WAT is the major source of elevated circulating pro-inflammatory factors [210]. WAT inflammation 
thereby involves both adipocytes and different immune cells that reside within WAT. Activation of the 
NF-B and AP-1 pathways in adipocytes is a critical event in this process as it leads to expression and 
secretion of pro-inflammatory cytokines but also to adipocyte insulin resistance because IKK and JNK 
are able to phosphorylate IRS1 at inhibitory serine residues [211]. Consequently, JNK deletion 
ameliorates insulin resistance and improves insulin receptor signaling in obese animals [212]. 
 To date, it is unknown which primary stimulus sets off the inflammatory reaction, but a 
number of aberrantly active cellular processes in WAT of obese subjects were shown to contribute. 
The presence of pro-inflammatory cytokines promotes IKK and JNK activation and indeed treatment 
of adipocytes with TNF inhibits IRS1 action. In contrast, animals with disrupted TNF signaling are 
protected from obesity-induced insulin resistance [211, 213]. High levels of free fatty acids that 
prevail in obesity are able to induce pro-inflammatory TLR signaling and consequently, TLR4 
deletion rescues animals from obesity-induced insulin-resistance [214]. Furthermore, ROS levels are 
aberrantly high in accumulated fat producing oxidative stress and, as a result, NF-B/AP-1 signaling 
[215]. If the capacity of adipocytes to store fat is exceeded, ER stress arises and free fatty acids leak 
into the cytoplasm where they in turn activate JNK [216]. The expansion of adipocytes might also 
outbalance angiogenesis, which leads to tissue hypoxia and the induction of hypoxia-inducible factor 
1 (HIF-1) that itself promotes pro-inflammatory cytokine expression [217]. In combination, ER 
stress and hypoxia exacerbate adipocyte necrosis. The dying cells then nucleate the formation of 
crown-like structures (areas of necrotic cells surrounded by macrophages), which are absent in lean 
animals [218]. 
 Adipose tissue macrophages (ATMs) are plastic cells that may polarize towards an anti-
inflammatory M2 or a pro-inflammatory M1 state. The two phenotypes are characterized by the 
distinct sets of cytokines that they express. Hence, the highly inflammatory TNF, IL-1 and IL-6 are 
secreted by M1 macrophages while M2 macrophages produce anti-inflammatory factors like IL-10. In 
WAT of lean animals, M2 macrophages are  more prominent than M1 macrophages. Their 
polarization is driven by adipocyte-derived IL-13, IL-4 and adiponectin as well as the prevalence of 
unsaturated free fatty acids leading to PPAR activation [219-221]. Accordingly, myeloid ablation of 
PPAR or PPAR/ impairs M2 skewing and fosters inflammation and insulin resistance [219, 222]. 
M2 macrophages exhibit an oxidative metabolic profile and PGC-1 is essential in initiating M2 
polarization [223]. 
 In contrast, M1 macrophages are highly enriched in WAT of obese animals where they 
amplify and sustain tissue inflammation [224, 225]. The altered cytokine/adipokine profile in fat, high 
levels of saturated free fatty acids and the emergence of crown-like structures promote the phenotypic 
switch from M2 to M1 macrophages [226]. M1 macrophages also express MCP-1, which attracts 
monocytes that migrate from the circulation into WAT where they differentiate into M1 macrophages 
further perpetuating inflammation. Adipose tissue-specific overexpressing of MCP-1 thus renders 
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animals insulin resistant, while deletion of the MCP-1 receptor CCR2 prevents M1 macrophage 
accumulation and maintains insulin sensitivity under high fat feeding [227-229]. Similarly, myeloid 
deletion of TLR4, JNK or IKK interferes with M1 macrophage polarization and consequently rescues 
insulin sensitivity on a high fat diet without differences in body weight gain [230-232]. 
 Besides ATMs, other immune cells contribute to both the anti-inflammatory, insulin sensitive, 
and the pro-inflammatory, insulin resistant state, respectively. Eosinophils, CD4+ regulatory T and 
Th2 cells all reside in WAT of lean animals where they preserve M2 macrophage activation and 
insulin sensitivity while the T cell balance in obese animals tips towards Th1 cells that secret IFN, 
hence skewing macrophages towards the M1 phenotype [233-236]. This polarization is further 
advanced by pro-inflammatory neutrophils, CD8+ effector T cells, and B cells that all have been 
detected in WAT in the early stages of obesity [237-239]. Therefore, depletion of immune cells types 
associated with M1 polarization or induction of M2-sustaining immune cells ameliorates insulin 
resistance [233, 234, 239, 240]. 
 In other organs, inflammatory reactions during the course of obesity have received less 
attention. The liver plays a major role in glucose metabolism due to hepatic gluconeogenesis. M1 
polarization of Kuppfer cells (liver macrophages) is now thought to contribute to hepatic 
inflammation, insulin resistance and steatosis. Recently, pancreatic  cell failure has also been linked 
to islet inflammation and M1 macrophage accumulation [241]. It therefore appears that inflammation 
with M1 macrophage polarization could be a general mechanism underlying organ dysfunction in 
obesity. 
 The situation in skeletal muscle is somewhat less clear. Intramuscular fat depots form in obese 
animals and attract inflammatory macrophages, however to a much smaller extent compared to bona 
fide adipose tissue [224]. These macrophages exert a negative influence on muscle insulin sensitivity 
as shown in obese animals with myeloid deletion of either JNK or IKK [231, 232]. In these models, 
inhibition of M1 macrophage activation preserved muscle insulin sensitivity [231, 232]. The same 
effect was observed after depletion of Cd11c+ cells that correspond to the main M1 macrophage 
subset in muscle [242]. Inversely, even lean animals with myeloid deletion of PPAR developed 
muscle insulin resistance, which deteriorated in the obese state due to impaired M2 macrophage 
polarization [243]. In contrast, myeloid deletion of PPAR/ or TLR4 did not entail any effect on 
muscle insulin sensitivity [219, 230].  
 These observations imply that skeletal muscle insulin resistance is at least partially regulated 
by mechanisms that are different from WAT. Investigating these common and distinct processes in 
skeletal muscle warrants further studies. The caveat of myeloid deletion approaches is however that all 
macrophages in the body are polarized towards one or the other phenotype. Distinguishing between 
purely skeletal muscle-specific cross-talk of macrophages and myocytes versus whole body effects on 
the muscle e.g. through generally lower circulating cytokine levels remains a difficult endeavor. 
Future experiments will have to discern the exact role of M1 and M2 macrophages in skeletal muscle 
under conditions of obesity.  
 
 
3.3 Inflammatory pathways in skeletal muscle  
 
 Adult skeletal muscle contains substantial amounts of different NF-B family members, their 
role in muscle physiology is however not fully resolved. It is unclear whether  NF-B is a pro-
myogenic or an anti-myogenic factor during muscle differentiation as relevant data are conflicting, but 
suppression of myogenesis by means of inhibiting MyoD, myogenin and myofibrillar gene expression 
has been linked to canonical NF-B signaling [244-252]. In contrast, noncanonical NF-B signaling 
that involves IKK and RelB does not affect myogenesis but drives an oxidative muscle fiber switch 
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by targeting PGC-1 which stimulates mitochondrial biogenesis [253]. Exercise-dependent NF-B 
activation has also been reported in skeletal muscle and potentially induces ROS defense, regeneration 
of damaged fibers and adaptations in fuel metabolism [254-256].  
 In muscle pathology, inflammatory reactions accompany a number of disorders like cachexia, 
muscular dystrophy, atrophy, and inflammatory myopathies [257]. NF-B activation in these contexts 
is a well-established disease mechanism that contributes significantly to deterioration of muscle 
function. This also is evident in mice with skeletal muscle-specific overexpression of IKK which 
causes severe muscle wasting while muscle-specific deletion of this kinase improves strength and 
counteracts denervation-induced atrophy and fiber type changes [258, 259]. Moreover, the latter 
model, similar to a p65 deletion model, regenerates faster from injury as inflammation is substantially 
inhibited in both mouse lines [252, 259]. 
 Regeneration of skeletal muscle requires the activation of satellite cells (muscle stem cells), 
their fusion to damaged fibers or the formation of new fibers depending on the degree of injury. 
Satellite cell proliferation is stimulated by IL-6 while IL-4 promotes myoblast fusion [260, 261]. 
Satellite cells also attract and interact with monocytes/macrophages to foster muscle growth [262]. 
Therefore, macrophages are also engaged in the different stages of regeneration: M1 macrophages 
(CD68+/CD163-) readily remove cellular debris by phagocytosis directly after injury and contribute to 
satellite cell activation while M2 macrophages (CD68-/CD163+) invade the tissue later [263]. They 
promote satellite cell differentiation and muscle growth in later regenerative stages to restore muscle 
function [264]. The M1/M2 macrophage switch is presumably initiated by muscle-derived IL-4 [261]. 
In dystrophic muscle, M1 macrophage activation and concomitant M2 macrophage repression e.g. by 
IFN exacerbates muscle wasting in DMD while conversely, symptoms are alleviated by IL-10, which 
activates M2 and represses M1 macrophages [265, 266]. 
 
 
4 PGC-1 coactivators and inflammation in skeletal muscle  
 
4.1 Anti-inflammatory effect of exercise 
 
 Skeletal muscle has been recognized as an endocrine organ that releases myokines (muscle-
derived cytokines) like IL-6, IL-8, and IL-15 during contraction [267]. These myokines presumably 
mediate beneficial effects of exercise both on the muscle itself and on distant organs. IL-6 has received 
most of the attention and the majority of studies deal with this myokine. The induction of IL-6 after 
exercise was speculated to be under the control of nuclear factor of activated T cells (NFAT) and/or 
p38/MAPK as opposed to NF-B during inflammatory reactions [268]. While elevated IL-6 levels are 
also associated with chronic inflammation, the contraction-induced rise of IL-6 is transient and thus 
not detrimental. Accordingly, IL-6 infusion increases insulin-stimulated glucose disposal in humans 
whereas deletion of IL-6 in mice results in mature-onset diabetes [269, 270]. Importantly, IL-6 
receptor expression is augmented concomitantly to IL-6 post exercise. This heightens “IL-6 
sensitivity” while reciprocally, under conditions of chronic inflammation “IL-6 sensitivity” might be 
lost (analogous to insulin resistance with high levels of insulin) [271]. 
 Diseases that are associated with a systemic, low-grade inflammation may be antagonized by 
physical activity e.g. diabetes, sarcopenia, and neurodegeneration [272-275]. Muscle-derived IL-6 
preludes expression of the anti-inflammatory cytokines IL-1Ra and IL-10 in blood while inhibiting 
pro-inflammatory TNF production [276, 277]. This skews the immune reaction towards a type 2 
response.  
 Following contraction, plasma levels of immunomodulatory hormones like epinephrine, 
cortisol, growth hormone and prolactin are all high and suppress inflammatory reactions [272]. On 
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monocytes, exercises reduce TLR1, TLR2, and TLR4 expression and function, alongside a decrease in 
major histocompatibility complex II and costimulatory molecules rendering these cells less 
inflammatory [278]. Potentiation of these effects after very strenuous training leads to temporary 
immunodepression as observed in high-performance athletes [272]. 
 
 
4.2 Mutual influence of inflammatory factors and PGC-1s  
 
 Inflammatory stimuli affect endogenous PGC-1 coactivator levels in different organs whereby 
LPS-induced sepsis is the most extensively studied model in this regard. In heart, kidney, and liver, 
PGC-1, ERR and MCAD mRNA was markedly reduced 16h after LPS injection [279]. 
Furthermore, in cardiac tissue, inflammation-dependent PGC-1 repression was further confirmed in 
vitro and in vivo, which could be rescued by inhibiting the NF-B pathway [280-282]. Sepsis-
associated acute kidney injury is associated with swollen, dysfunctional mitochondria and reduced 
PGC-1 levels that correlate with renal impairment [283]. This phenotype can be recapitulated by 
treatment of tubular cells with TNF and reversed by excess PGC-1 while lack of this coactivator 
results in persistent kidney injury after endotoxemia [283]. In contrast, one study reported an opposite 
regulation of PGC-1 and PGC-1 in liver of septic mice, as both coactivators were induced in a 
TLR2-dependent manner [284].  
 In skeletal muscle, the regulation of PGC-1 coactivators by inflammatory stimuli is 
ambiguous. An early study found that LPS, TNF, and IL-1 augment PGC-1 expression resulting 
in increased oxidative phosphorylation while more recently, sepsis was shown to lower PGC-1 and 
PGC-1 in skeletal muscle of rats [61, 285]. In support of these data, PGC-1 and PGC-1 are also 
reduced in diaphragm after LPS administration with concomitant decrease in fatty acid oxidation 
[286]. A more careful examination of the time-course revealed that intraperitoneal injection of LPS 
induced PGC-1 in skeletal muscle after 2h, but decreased its expression after 24h, suggesting a short-
term up- but a long-term down-regulation [287]. This model is also well in line with the induction of 
PGC-1 after exercise in the transient presence of myokines that return to basal levels quickly as 
opposed to the chronic, low-grade inflammation observed in metabolic disorders with dampened PGC-
1 coactivator levels in skeletal muscle.  A repression of PGC-1 and PGC-1 upon chronic TNF or 
IL-1 exposure was also observed in C2C12 myotubes [288]. Importantly, inflammatory stimulation 
with the activation of classical NF-B signaling clearly impaired the oxidative phenotype in this 
system [288]. Cell culture studies with palmitate further back the abovementioned, dual regulation as 
long-term treatment repressed, while short-term treatment increased PGC-1α expression [289]. 
However, one study also associated long-term palmitate administration with an increase in PGC-1 in 
vascular smooth muscle cells [290]. 
 A pathological condition frequently associated with muscle wasting and low oxidative 
capacity is chronic obstructive pulmonary disease (COPD). COPD patients also exhibit high TNF 
levels in skeletal muscle alongside decreased PGC-1 expression [291]. This repression can be 
replicated in vitro by chronically treating the C2C12 muscle cell line with TNF The subsequent 
inhibition of oxidative phosphorylation is dependent on NF-B [291, 292]. Similarly, TNF is 
augmented in mice exposed to cigarette smoke while PGC-1 levels in skeletal muscle of these 
animals are diminished [292]. The impairment in expression of PGC-1 and some of its target genes is 
more pronounced in oxidative muscles [292]. Of note, plasma TNF levels in COPD patients 
negatively correlate with PPAR expression in skeletal muscle [293]. Overall, these data imply that 
chronic inflammatory stimulation and especially NF-B signaling lead to a suppression of PGC-1 
coactivator levels. 
Review in Seminars in Immunopathology on “Metabolic Syndrome” (01/2014) 
20 
 An inverse, body mass index-independent correlation between PGC-1 and IL-6 as well as 
TNF expression is also present in skeletal muscle of diabetic patients [151]. In accordance, mouse 
models that lack PGC-1 in skeletal muscle or only express it heterozygously display higher IL-6 
levels in muscle and blood [151]. Complete lack of muscle PGC-1 further promotes the expression of 
pro-inflammatory markers like TNF and CD68 in skeletal muscle [151]. After exercise that increases 
PGC-1 levels in wild-type mice, excessive TNF expression in muscle and blood can be observed in 
this model [105]. Therefore, low PGC-1 levels in skeletal muscle are associated with inflammatory 
processes in muscle and the appearance of circulating pro-inflammatory cytokines. 
 A causal relationship between PGC-1 coactivators and inflammation has recently been 
established. PGC-1 and PGC-1 were shown to diminish the increase in pro-inflammatory cytokine 
expression elicited by TNF, TLR agonists and saturated free fatty acids in C2C12 muscle cells [294]. 
In human aortic smooth muscle and endothelial cells PGC-1 likewise decreased TNF-induced 
VCAM-1 and MCP-1 expression [295]. Mechanistically, the PGC-1 coactivators target the NF-B 
pathway and for example dampen expression of luciferase from an NF-B-drive reporter in vitro and 
in vivo [142, 294]. More precisely, the PGC-1s lower phosphorylation of p65 in C2C12 cells and 
muscle-specific PGC-1 transgenic mice [100, 294]. One study however found elevated p65 
phosphorylation levels in this model and no difference between wild-type and transgenic mice 
concerning muscle IL-6 and TNF expression after short-term, intraperitoneal LPS injection [296]. In 
vitro, transrepression by PPAR is a second mechanism that contributes to the repression of pro-
inflammatory cytokines in skeletal muscle cells [294].  
 Together, these results suggest that PGC-1 coactivators and inflammatory processes in skeletal 
muscle are linked in a reciprocal manner (Fig. 2). Therefore, high PGC-1 expression not only 
determines an oxidative metabolic state, but also favors an anti-inflammatory environment (Fig. 2A). 
Inversely, pro-inflammatory cytokines suppress PGC-1 coactivators leading to a more glycolytic 
metabolism in a highly inflammatory environment (Fig. 2B). The NF-B pathways appears to be a 
nodal point in this mutual repressive action as NF-B signaling strongly induces pro-inflammatory 
genes and at the same time suppresses PGC-1 coactivator expression. Conversely, at least canonical 
NF-B signaling can be restrained by PGC-1 coactivators constituting an interdependent, negative, 
molecular regulation of oxidative metabolism and inflammation in muscle cells (Fig. 2).  
 In macrophages, this antagonism has previously been described during alternative activation 
which is associated with a decrease in the expression of pro-inflammatory markers and requires PGC-
1 induction [223]. These M2 macrophages show signs of an oxidative metabolic program as opposed 
to M1 macrophages that rely mainly on glycolysis as energy producing pathway. PGC-1 expression 
in macrophages furthermore drives the generation of mitochondrial ROS, which are vital in pathogen 
clearance [297]. The role of PGC-1 in macrophages is not well understood but it likely participates in 
M2-like polarization as hypothesized for macrophages in epidydimal adipose tissue while it is 
downregulated after LPS exposure which leads to M1 macrophage polarization [298, 299]. PGC-1 
inhibition in this case enables ROS production as many ROS detoxifying enzymes are among PGC-1 
target genes [299]. 
 M1 and M2 macrophage-polarizing signals are mutually exclusive and thus preclude the 
opposite activation state. The anti-inflammatory cytokines IL-4, IL-10, and Il-13, for example, 
suppress M1 macrophage activation because they disturb NF-B signaling and STAT1 activation by 
inducing inhibitory p50 dimers and STAT3/STAT6 [300, 301]. STAT6 is an important molecular 
determinant of M2 macrophage activation that cooperates with Krüppel-like factor 4 (KLF4) to induce 
anti-inflammatory M2 and inhibit pro-inflammatory M1 genes [302]. Similarly, KLF2 also impairs 
NF-B activation [303]. PPAR and PPAR/ are required for M2 macrophage polarization. They 
induce both a more oxidative metabolic program within these immune cells and simultaneously 
Review in Seminars in Immunopathology on “Metabolic Syndrome” (01/2014) 
21 
transrepress pro-inflammatory promoters, which renders these nuclear receptors central players in the 
dichotomy between M1 and M2 macrophages reflecting the antagonism between oxidative metabolism 
and inflammatory gene expression [219, 222, 304]. If this adverse regulation that we propose to take 
place in macrophages and muscle cells also plays a role in other tissues remains to be determined. For 
example, canonical NF-B signaling has previously been associated with positive regulation of 
mitochondrial biogenesis in embryonic fibroblasts and cancer cells [305, 306]. 
 Transcription factors implicated in mitochondrial biogenesis are also potent inducers of the 
anti-inflammatory cytokines IL-10 and IL-1Ra in both macrophages and but also liver cells reinforcing 
opposite roles for oxidative metabolism and inflammation respectively [307]. IL-1Ra and IL-15 
induction in primary hepatocytes after fasting, exercise, glucagon, or cAMP exposure which coincides 
with PGC-1 expression in these cells further confirms the association [308]. Elevation of IL-1Ra and 
IL-15 is thereby dependent on PPAR [308]. PPAR thus seems to play a dual role in mediating the 
anti-inflammatory effect of oxidative metabolism: while this nuclear receptor acts transrepressive on 
the induction of NF-B-dependent, pro-inflammatory genes, it also promotes the expression of anti-
inflammatory cytokines, at least in hepatocytes. Both activities in concert then shift the balance 
between pro- and anti-inflammatory gene expression. Similarly, conjugated linoleic acid ameliorates 
colitis in a model of inflammatory bowel disease by targeting PPAR [309]. The treated mice show 
higher PGC-1 levels while NF-B activation and TNF expression are decreased [309]. 
 A direct negative effect of any of the PGC-1 coactivators on pro-inflammatory gene 
expression is somewhat unlikely, as they have been described unequivocally as transcription 
coactivators that recruit factors which facilitate transcription at the promoter. In contrast, no 
corepressor activity for the PGC-1s is known so far. Besides PPAR-dependent transactivation and 
transrepression, direct interaction of PGC-1 or PGC-1 with NF-B family members has been 
reported in various cell types. In bone marrow stromal cells, constitutive binding of PGC-1 to p65 
and p50 was decreased in the presence of PPAR ligands leading to the hypothesis that PGC-1 is a 
shared coactivator that NF-B and PPAR compete for [310]. In hepatocytes, free fatty acids induce a 
p50-PGC-1 interaction and binding of this complex to the IL-10 promoter however with uncertain 
results concerning the role of PGC-1 in regard to coactivator or corepressor activity at this site [311]. 
In cardiomyocytes, binding of PGC-1 to p65 that increased upon TNF exposure was detected [312]. 
The authors propose that p65 inhibits PGC-1 activity leading to a drop in PDK4 and subsequently 
higher glucose oxidation rates [312]. This would fit the model of NF-B-dependent blockade of 
oxidative metabolism; some ambiguities concerning the exact mechanism however remain to be 
uncovered. In skeletal muscle cells, no direct interaction of p65 or any other NF-B family member 
and PGC-1 or PGC-1 has been found.  
 PGC-1 may also interfere with upstream NF-B signaling. An induction of IB has been 
observed in quadriceps of whole body PGC-1 transgenic mice in vivo but not in vitro while Bcl3 
interacts with PGC-1 synergistically to coactivate ERR and PPAR in cardiomyocytes [313, 314]. 
The reciprocity of oxidative metabolism and inflammatory signaling may thus extend beyond the 
antithetic roles of PGC-1 and NF-B at the transcription activation level and could involve 
mechanisms like cofactor competition and upregulation of phosphatases. The molecular details of such 
processes however remain to be investigated in future studies.  
 Functionally, it is clear that inflammation in WAT substantially contributes to the 
development of insulin resistance under conditions of overfeeding with detrimental crosstalk between 
immune and fat cells (see above). Cues that this mechanism might also be in place in skeletal muscle 
derive from myeloid deletion studies where silencing of the pro-inflammatory genes JNK1, or IKK, 
in the hematopoietic compartment or depletion of Cd11c+ cells increased insulin-stimulated glucose 
disposal (which correlates to muscle insulin sensitivity) under high fat diet feeding conditions whereas 
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hematopoietic PPAR deletion had the opposite effect [231, 232, 242, 243]. M1 macrophage 
polarization thus seems to be associated with muscle insulin resistance while M2 polarization is linked 
to muscle insulin sensitivity. Accordingly, an accumulation of M1 macrophages in obese rodents and 
humans has been described and pro-inflammatory macrophage markers within skeletal muscle 
correlate with poor glycemic control in diabetic patients whereas anti-inflammatory markers correlate 
with improved parameters in this setting [315, 316]. . The model proposed here therefore implies that 
in the insulin sensitive state, M2 macrophages are the predominant phenotype in skeletal muscle (Fig. 
3). Endurance training, which increases PGC-1 in the muscle cells, leads to the release of myokines 
that further mediate the anti-inflammatory effects of exercise e.g. downregulation of certain TLRs on 
monocytes. In the ensuing anti-inflammatory environment, macrophages would remain polarized in an 
alternative activation state and retroact on myocytes through the release of anti-inflammatory factors 
that favor the maintenance of insulin sensitivity (Fig. 3). Indeed, a single bout of exercise has recently 
been shown to increase insulin sensitivity in murine skeletal muscle and entail a concomitant 
accumulation of M2 macrophages [317]. If the balance between muscle cells and M2 macrophages is 
lost, e.g. in the etiology of diabetes, a vicious cycle would commence ultimately resulting in insulin 
resistance in an inflamed environment. This involves a switch to M1 macrophages, the secretion of 
pro-inflammatory cytokines by both classically activated macrophages and muscle cells worsening 
insulin sensitivity on one hand and promoting inflammation on the other hand concomitant with a 
decrease in muscle oxidative capacity and PGC-1 coactivator levels (Fig. 3). The antagonism between 
oxidative metabolism and inflammatory signaling would thus not only provide an attractive 
explanation for the different states of muscle cells in healthy and obese subjects but is further extended 
to the macrophage phenotypes. High PGC-1 levels in skeletal muscle and high PGC-1 levels in M2 
macrophages would hereby correspond to the trained state while downregulation of PGC-1 
coactivators in both skeletal muscle and macrophages would translate into an insulin resistant, pro-
inflammatory environment in inactive, obese patients (Fig. 3). Detailed evidence for such a myocyte-
macrophage crosstalk remains to be provided.  
 In muscle diseases, such a model would also be feasible because ectopic expression of PGC-
1 ameliorated fiber integrity and function, for example in DMD, sarcopenia, a mitochondrial 
myopathy and denervation-induced fiber atrophy [100, 101, 140, 143]. Reducing the inflammatory 
reaction in these conditions likely explains at least a part of the beneficial PGC-1 effect as other 
strategies to counteract inflammation have proven useful e.g. in DMD [101, 265, 266]. Conversely, 
endurance training that fosters PGC-1 expression protects against fiber damage, muscle 
inflammation and soreness.  
 Taken together, muscle cells take active part in immune reactions and are thus able to 
influence immune cells e.g. in their activation state. The complex interplay between those cell types is 
only incompletely understood to date and further studies are needed to elucidate the molecular 
mechanisms underlying this crosstalk. The antagonism between PGC-1 coactivators and inflammatory 
processes should thereby receive special attention as an imbalance is associated with metabolic and 





 Metabolism and inflammation used to be considered as two completely independent processes 
in the body. In the past decade, it has become clear that both are tightly linked at multiple levels, 
which is particularly evident in cases where homeostasis is lost like nutritional overload. The 
dysregulation of metabolism is associated with an inflammatory reaction in different organs that 
significantly contributes to the development of insulin resistance while in the opposite, healthy state, 
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an anti-inflammatory environment prevails. We have focused here on this interaction in skeletal 
muscle, which is both metabolically and immunologically active. One of the nodal points in this 
context seems the crosstalk of oxidative metabolism through the PGC-1 coactivators and NF-B 
signaling that mutually suppress each other. It will be of prime interest to define this relationship in 
greater detail in the future and take pathological muscle conditions into account. This would pave the 
way for treatment strategies aimed not only at bringing back metabolic balance but also at halting 
inflammation to improve muscle structure and function. 
 Although no specific activators of PGC-1 or PGC-1 are available at the moment, exercise 
induces PGC-1 in skeletal muscle and training has been shown to counteract diseases with sterile 
inflammation like diabetes and neurodegeneration. Exercise capacity is furthermore a strong predictor 
of all-cause mortality while a sedentary lifestyle is a major risk factor for chronic diseases. Developing 
training regimes that optimally target an induction of oxidative metabolism and concomitantly block 
inflammation is a promising route to take as this would improve both the metabolic and the immune 






Figure 1 Schematic representation of the murine PGC-1 family members  and transcript variants. AD, 
activation domain; ID, inhibitory domain; RS, arginine-/serine-rich domain; RRM, RNA recognition 
and splicing motif; S, serine-rich domain; P, proline-rich domain; L, LXXLL or LLXXL motif; Q, 
glutamine-rich domain 1 and 2. Numbers indicate amino acid positions and refer to RefSeq transcripts; 
different N-terminal amino acid sequences corresponding to a different exon 1 and arise from 
alternative promoter usage are indicated; an asterisk indicates additional C-terminal amino acids that 
are not shared by all splice variants [27, 29, 35, 44-48, 318].  
 
 
Figure 2 Molecular mechanisms of the mutual antagonism between oxidative metabolism and 
inflammation in skeletal muscle. A PGC-1 coactivators negatively regulate inflammation. PGC-1 
coactivators are at the crossroad of cellular respiration and inflammation as PGC-1 and PGC-1 
coactivate a set of nuclear receptors and transcription factors to induce genes involved in oxidative 
metabolism. At the same time PGC-1 coactivators interfere with inflammatory signaling at different 
levels. PGC-1 and PGC-1 inhibit phosphorylation of the NF-B subunit p65 and thus restrain NF-
B signaling resulting in diminished expression of pro-inflammatory cytokines. Both coactivators also 
induce PPAR. This nuclear receptor acts transrepressive on the promoters of pro-inflammatory genes 
equally limiting their expression. Inversely, expression of some anti-inflammatory genes has been 
shown to depend on PPAR. Whether PGC-1 and/or PGC-1 play a direct role in coactivating 
PPAR on the promoters of those genes is not known. Taken together, PGC-1 coactivators lower pro-
inflammatory but induce anti-inflammatory genes contributing to a less inflamed environment. B 
Classical NF-B signaling inhibits PGC-1 expression. Inflammatory stimuli like NF-B activation 
reduce expression levels of both PGC-1 and PGC-1 in various contexts. Expression of PGC-1 is 
driven by CREB and MEF2, the latter being coactivated by PGC-1α in a positive autoregulatory loop. 
NF-B might constrain binding of those transcription factors to the PGC-1 promoter, the exact 
mechanism of this inhibition is however not known. Decreased PGC-1 coactivator expression in turn 
results in a decline of oxidative metabolism. PGC-1, peroxisome proliferator-activated receptor  
coactivator 1; PPAR, peroxisome proliferator-activated receptor ; PPRE, PPAR response element; 
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MEF2, myocyte enhancer factor 2; CREB, cAMP response element binding protein; CRE, cAMP 
response element 
 
Figure 3 Potential crosstalk of skeletal muscle and the immune system. In the trained state, skeletal 
muscle is insulin sensitive and PGC-1 levels are chronically increased. Muscle contraction leads to 
the release of myokines, which mediate many of the beneficial effect of exercise both locally and 
systemically. Analogous to the events in fat tissue of lean animals and humans, exposure of muscle-
resident macrophages to these myokines could polarize them towards an anti-inflammatory M2 
phenotype. These M2 macrophages in turn further secrete anti-inflammatory factors that help to 
maintain skeletal muscle in an insulin sensitive state. On the other side of the spectrum, PGC-1 and 
PGC-1 are chronically lowered in skeletal muscle of inactive/obese/diabetic animals or patients. The 
release of pro-inflammatory factors from this insulin resistant muscle tissue presumably drives 
polarization of muscle-resident macrophages towards a pro-inflammatory M1 phenotype. M1 
macrophages themselves release more pro-inflammatory cytokines, which negatively act back onto the 
muscle contributing to deterioration of muscle contractile and metabolic function. In macrophages, 
PGC-1 has been shown to be required for M2 macrophage activation and PGC-1 seems to be 
involved in this process at least in some contexts while production of reactive oxygen species typical 
for M1 macrophage activation is only possible in the absence of PGC-1. A comprehensive 
understanding of the regulation of both coactivators in different macrophage activation states is 
however still missing. PGC-1, peroxisome proliferator-activated receptor  coactivator 1; M1, 






This review is dedicated to the memory of Dr. Martine Christe. Research in our laboratory is 
supported by the Swiss National Science Foundation, the Muscular Dystrophy Association USA 
(MDA), the SwissLife ‘Jubiläumsstiftung für Volksgesundheit und medizinische Forschung’, the 
Swiss Society for Research on Muscle Diseases (SSEM), the Swiss Diabetes Association, the Roche 
Research Foundation, the United Mitochondrial Disease Foundation (UMDF), the Association 
Française contre les Myopathies (AFM), the Gebert-Rüf Foundation “Rare Diseases” Program, the 
University of Basel and the Biozentrum. 
 
Conflict of interest statement 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Review in Seminars in Immunopathology on “Metabolic Syndrome” (01/2014) 
43 
311.  Morari J, Torsoni AS, Anhe GF, Roman EA, Cintra DE, Ward LS, Bordin S, Velloso LA (2010) The 
role of proliferator‐activated receptor gamma coactivator‐1alpha in the fatty‐acid‐dependent 
transcriptional control of interleukin‐10 in hepatic cells of rodents. Metabolism: clinical and 
experimental 59: 215‐23 
312.  Alvarez‐Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, Feldman AM, Laguna JC, 
Vazquez‐Carrera M (2010) The p65 subunit of NF‐kappaB binds to PGC‐1alpha, linking 
inflammation and metabolic disturbances in cardiac cells. Cardiovascular research 87: 449‐58 
313.  Liang H, Balas B, Tantiwong P, Dube J, Goodpaster BH, O'Doherty RM, DeFronzo RA, 
Richardson A, Musi N, Ward WF (2009) Whole body overexpression of PGC‐1alpha has 
opposite effects on hepatic and muscle insulin sensitivity. American journal of physiology. 
Endocrinology and metabolism 296: E945‐54 
314.  Yang J, Williams RS, Kelly DP (2009) Bcl3 interacts cooperatively with peroxisome 
proliferator‐activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate 
nuclear receptors estrogen‐related receptor alpha and PPARalpha. Molecular and cellular 
biology 29: 4091‐102 
315.  Fink LN, Oberbach A, Costford SR, Chan KL, Sams A, Bluher M, Klip A (2013) Expression of 
anti‐inflammatory macrophage genes within skeletal muscle correlates with insulin 
sensitivity in human obesity and type 2 diabetes. Diabetologia 56: 1623‐8 
316.  Fink LN, Costford SR, Lee YS, Jensen TE, Bilan PJ, Oberbach A, Bluher M, Olefsky JM, Sams A, 
Klip A (2013) Pro‐Inflammatory macrophages increase in skeletal muscle of high fat‐Fed mice 
and correlate with metabolic risk markers in humans. Obesity  
317.  Ikeda SI, Tamura Y, Kakehi S, Takeno K, Kawaguchi M, Watanabe T, Sato F, Ogihara T, 
Kanazawa A, Fujitani Y, Kawamori R, Watada H (2013) Exercise‐induced enhancement of 
insulin sensitivity is associated with accumulation of M2‐polarized macrophages in mouse 
skeletal muscle. Biochem Biophys Res Commun  
318.  Sadana P, Park EA (2007) Characterization of the transactivation domain in the peroxisome‐
proliferator‐activated receptor gamma co‐activator (PGC‐1). Biochem J 403: 511‐8 
 
 



